Evidence map›Paper›PMID 27127599›Full record

ArticleNeurology international2016

Revisiting the Term Neuroprotection in Chronic and Degenerative Diseases.

Marco Orsini, Osvaldo J M Nascimento, Andre P C Matta, Carlos Henrique Melo Reis, Olivia Gameiro de Souza, Victor Hugo Bastos, Rayele Moreira, Pedro Ribeiro, Stenio Fiorelli, Pietro Novellino and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Metabolic Syndrome and Neuroprotection.Frontiers in neuroscience · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marco Orsini
Osvaldo J M NascimentoDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Andre P C MattaDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Carlos Henrique Melo ReisNeurology Service, Nova Iguaçu Hospital , Posse.
Olivia Gameiro de SouzaDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Victor Hugo BastosBrain Mapping Laboratory and Electroencephalogram, Federal University of Rio de Janeiro; Brain Mapping and Functionality Laboratory, Federal University of Piauí
Rayele MoreiraBrain Mapping Laboratory and Electroencephalogram, Federal University of Rio de Janeiro; Brain Mapping and Functionality Laboratory, Federal University of Piauí
Pedro RibeiroBrain Mapping Laboratory and Electroencephalogram, Federal University of Rio de Janeiro; Brain Mapping and Functionality Laboratory, Federal University of Piauí
Stenio FiorelliSeverino Sombra University Center, School of Medicine , Vassouras.
Pietro NovellinoSeverino Sombra University Center, School of Medicine , Vassouras.
Bruno PessoaDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Mariana CunhaDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Camila PupeDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Pedro S MoralesDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Pedro F Moreira FilhoDepartment of Neurology, Antonio Pedro University Hospital, Fluminense Federal University , Niterói.
Eduardo Lima TrajanoSeverino Sombra University Center, School of Medicine , Vassouras.
Acary Bulle OliveiraDepartment of Neurology, Federal University of São Paulo , Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thanks to the development of several new researches, the lifetime presented a significant increase, even so, we still have many obstacles to overcome - among them, manage and get responses regarding neurodegenerative diseases. Where we are in the understanding of neuroprotection? Do we really have protective therapies for diseases considered degeneratives such as amyotrophic lateral sclerosis and its variants, Parkinson's disease, Alzheimer's disease and many others? Neuroprotection is defined by many researches as interactions and interventions that can slow down or even inhibit the progression of neuronal degeneration process. We make some considerations on this neuroprotective effect.

Indexed as

degenerative diseasesNeuroplasticityneuroprotection

Identifiers

PMID27127599
PMCPMC4830365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.